Compare Braze Inc (BRZE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Novo Nordisk A/S — how do they compare? Braze Inc trades at $28.27 (market cap $3.18B), while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 65.4× Braze Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Braze Inc pays none. Which is the better fit depends on your goals.
| BRZE | NVO | |
|---|---|---|
Market Cap | $3.18B | $207.85B |
Sector | Technology | Health |
52-Week High | $36.19 | $63.98 |
52-Week Low | $15.79 | $35.29 |
Enterprise Value | $2.87B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRZE trades at $27.68, down 3.72% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth is strong at 30% year-over-year, though the company remains unprofitable with a net margin of -15.51%. Recent news highlights insider selling and a 15% weekly rebound amid AI sector momentum.
The stock offers growth exposure with a consensus price target of $34.78, but risks include persistent losses, competitive pressures, and high valuation multiples. Analyst sentiment is overwhelmingly bullish, yet profitability challenges and insider sales warrant caution for investors seeking near-term returns.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
